Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes with better overall survival, but only 15-40% of the patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Raza, Afsheen, Mohsen, Reyad, Kanbour, Aladdin, Zar Gul, Abdul Rehman, Philip, Anite, Vijayakumar, Suma, Hydrose, Shereena, Prabhu, Kirti S., Al-Suwaidi, Aisha Khamis, Inchakalody, Varghese Philipose, Merhi, Maysaloun, Abo El-Ella, Dina M., Tauro, Melissa Annrose, Akbar, Shayista, Al-Bozom, Issam, Abualainin, Wafa, Al-Abdulla, Rajaa, Sirriya, Shaza Abu, Hassnad, Suparna, Uddin, Shahab, Mohamed Ibrahim, Mohamed Izham, Al Homsi, Ussama, Demime, Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225547/
https://www.ncbi.nlm.nih.gov/pubmed/37256148
http://dx.doi.org/10.3389/fimmu.2023.1157100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225547/
https://www.ncbi.nlm.nih.gov/pubmed/37256148
http://dx.doi.org/10.3389/fimmu.2023.1157100

Ejemplares similares